Compare Roopa Industries with Similar Stocks
Dashboard
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 8.82%
- Low ability to service debt as the company has a high Debt to EBITDA ratio of 3.82 times
With a growth in Operating Profit of 56.65%, the company declared Very Positive results in Mar 26
With ROCE of 15.6, it has a Very Attractive valuation with a 1.5 Enterprise value to Capital Employed
Majority shareholders : Non Institution
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
INR 39 Cr (Micro Cap)
10.00
36
0.00%
1.68
23.69%
2.36
Total Returns (Price + Dividend) 
Roopa Industries for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Roopa Industries Ltd Upgraded to Hold on Improved Technicals and Financial Performance
Roopa Industries Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 14 July 2026. This change reflects a notable improvement in the company’s technical indicators, financial results, valuation metrics, and overall quality assessment, signalling a cautious but positive outlook for investors.
Read full news article
Roopa Industries Ltd is Rated Sell
Roopa Industries Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 23 June 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 08 July 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trend, and technical outlook.
Read full news article
Roopa Industries Downgraded to Sell Amid Mixed Financials and Weak Technicals
Roopa Industries Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 23 June 2026. This shift reflects a complex interplay of deteriorating technical indicators, mixed financial trends, valuation considerations, and overall quality assessments, signalling caution for investors despite some recent positive earnings results.
Read full news article Announcements 
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
11-Jul-2026 | Source : BSESubmission of Certificate U/R 74(5) of SEBI (DP) Regulations 2018
Closure of Trading Window
25-Jun-2026 | Source : BSEIntimation of Closure of Trading Window for the quarter ended 30 June 2026
Submission Of Newspaper Clipping Pursuant To SEBI Circular No. SEBI/HO/38/13/11(2)2026- MIRSD-Pod/1/3750/2026 Dated January 30 2026
15-Jun-2026 | Source : BSESubmission of Newspaper Clipping
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Non Institution
None
Held by 0 Schemes
Held by 1 FIIs (0.25%)
Star Niochem Pvt Limited (18.91%)
Sangeetha S (9.51%)
41.0%
Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ
QoQ Growth in quarter ended Mar 2026 is -10.14% vs 16.70% in Dec 2025
QoQ Growth in quarter ended Mar 2026 is -285.71% vs 67.39% in Dec 2025
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is 6.15% vs 106.60% in Sep 2024
Growth in half year ended Sep 2025 is -12.79% vs 7.50% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'25
YoY Growth in nine months ended Dec 2025 is 7.17% vs 87.94% in Dec 2024
YoY Growth in nine months ended Dec 2025 is -6.17% vs 51.40% in Dec 2024
Annual Results Snapshot (Standalone) - Mar'26
YoY Growth in year ended Mar 2026 is 5.64% vs 71.36% in Mar 2025
YoY Growth in year ended Mar 2026 is -96.06% vs 33.55% in Mar 2025






